UOK-120人类原发性乳头状肾细胞癌细胞系 BioVector NTCC保藏中心

BioVector® NTCC® UOK-120人类原发性乳头状肾细胞癌细胞系

BioVector® UOK-120细胞系是一种人类肾细胞癌（RCC）细胞系，源自一名30岁男性原发性乳头状肾细胞癌。其特别之处在于携带t(X;1)(p11.2;q21.2)染色体易位，从而产生PRCC-TFE3融合基因。
主要特点
来源：一名30岁男性的原发性乳头状肾细胞癌。
遗传特征：其决定性特征是染色体易位导致PRCC-TFE3基因融合。这种TFE3融合基因驱动了细胞的转化（癌变）表型。
表型：与其他TFE3融合型肾细胞癌细胞系相比，UOK-120细胞系被描述为具有更强的间充质表型。其存活高度依赖于PRCC-TFE3融合蛋白的表达。
TFE3融合的作用：研究表明，TFE3融合蛋白在UOK-120和其他TFE3融合型细胞系中能够驱动某些细胞过程，包括氧化代谢和铁死亡抵抗。
研究用途：作为研究TFE3融合型肾细胞癌的重要模型，该类型肾癌是一种罕见但具有侵袭性的肾癌亚型。使用该细胞系的研究包括：
药物筛选：评估潜在的治疗药物。
基因表达研究：理解癌症中涉及的分子通路。
生物标志物研究：研究PD-L1等蛋白的表达与TFE3表达之间的关系。

The UOK-120 cell line is a human renal cell carcinoma (RCC) line, derived from a primary papillary renal cell carcinoma in a 30-year-old male. It is particularly notable for carrying a t(X;1)(p11.2;q21.2) translocation that creates a PRCC-TFE3 fusion gene.
Key characteristics
Origin: Primary papillary renal cell carcinoma from a 30-year-old male.
Genetic makeup: A defining feature is the PRCC-TFE3 gene fusion resulting from a chromosomal translocation. This TFE3 fusion drives the transformed (cancerous) phenotype.
Phenotype: The UOK-120 cell line is described as having a more mesenchymal phenotype compared to other TFE3-fusion RCC lines. Its viability is highly dependent on the expression of the PRCC-TFE3 fusion protein.
Role of TFE3 fusion: The TFE3 fusion protein has been shown to drive certain cellular processes, including oxidative metabolism and ferroptosis resistance, in UOK-120 and other TFE3-fusion lines.
Research use: It is used extensively as a model for studying TFE3-fusion renal cell carcinoma, which is a rare but aggressive subtype of kidney cancer. Research using this cell line includes:
Drug screening: For evaluating potential therapeutic agents.
Gene expression studies: To understand the molecular pathways involved in the cancer.
Biomarker studies: The expression of proteins like PD-L1 has been examined in relation to TFE3 expression.

Supplier来源:BioVector NTCC Inc.
Email: biovector@163.com
Website网址: http://www.biovector.net